GLP-1 · Aging clocks · Conference readout
Lilly and Novo report GLP-1 drugs slowed molecular “aging clocks” by about 2–3 years
At the Aging Research & Drug Discovery meeting (reported Oct 6, 2026), Novo (semaglutide) and Lilly (tirzepatide, using epigenetic clocks) said overweight or diabetic trial patients on GLP-1s had lower biological-age readouts than placebo. Novo put the difference at about two to three years, and it varied widely by clock type and organ. ARPA-H is funding a $38M Texas study of semaglutide in healthy adults over 60.
Caveat: These are company-reported conference readouts on surrogate aging clocks. They aren’t peer-reviewed, and they show no lifespan or healthspan outcome benefit. Aging clocks aren’t validated clinical endpoints.
MIT Technology Review →
Aging biology · Lipidomics · Cross-species
Lipid acyl-chain elongation identified as a conserved hallmark of aging (Nature Aging)
Published Oct 6, 2026. Cross-species, multi-tissue lipidomics in mice, C. elegans, Drosophila and humans found lipids shift toward longer acyl chains with age. Similar lengthening appears as human heart disease progresses, and dietary restriction shortened cardiac lipids in mice. The lipid remodeler Plb1 tracked lifespan in mice and had genetic support for a role in human frailty. Plb1 knockdown in worms reversed elongation and extended lifespan.
Caveat: The lifespan extension is in worms only. Human data are associative and genetic, and there’s no intervention or clinical test yet.
Nature Aging →
Nature Aging News & Views →
CRISPR · Beta-thalassemia · Routine care
Germany’s first routine-care CRISPR patient (exa-cel at Charité) is transfusion-independent
Charité Berlin reported (Oct 5–6, 2026) that a 19-year-old with transfusion-dependent beta-thalassemia, treated in May with exagamglogene autotemcel (exa-cel) as standard care, no longer needs transfusions four months later. Charité is Germany’s first qualified exa-cel center.
Caveat: This is a single patient with short follow-up. The EU approval is conditional, requires 15-year post-treatment monitoring, and limits treatment to specialized centers. It’s an institutional announcement, not new trial data.
The Microbiologist →
dpa via NAMPA →
Gene therapy · Diabetic retinopathy · Phase II
REGENXBIO/AbbVie sura-vec reaches three years in non-proliferative diabetic retinopathy (ALTITUDE Phase II)
Reported Oct 6, 2026 (data as of Aug 17, 2026). Surabgene lomparvovec (ABBV-RGX-314) is a one-time in-office AAV gene therapy that makes the eye produce its own anti-VEGF antibody fragment. At Dose Level 3, 60% of participants with three-year visits improved by 2 or more steps on the DRSS without additional DR treatment or vision-threatening events. Among 17 participants followed through three years, there was no intraocular inflammation and no new safety signals.
Caveat: This is a small Phase II, company-reported update, and the subgroups are small. It isn’t approved, and it isn’t a head-to-head comparison against standard anti-VEGF injections.
Longevity.Technology →
Progeria · p53 isoform · Preclinical
Senescence-inhibiting p53 isoform Δ133p53α attenuates accelerated aging in progeria mice (npj Aging)
Published Oct 7, 2026 (open access). In a Hutchinson-Gilford progeria mouse model, transgenic Δ133p53α lowered p21, IL-6 and γ-H2AX across tissues. It preserved aortic smooth muscle cells, skin dermis and dermal fat, eased kyphosis, and modestly increased median lifespan. The authors also report preliminary benefit in naturally aged mice.
Caveat: This is a transgenic mouse study. The natural-aging data are preliminary, and there’s no human therapy or trial.
npj Aging →
